Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionRestricted Stock Units · Derivative | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002304 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,087 Underlying: Common Stock · 4,362 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Tax withholdingCommon Stock | 1,990 | $65.95 | $131,240.50 |
DisclosureSEC source: 0001225208-24-002304 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,726 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionCommon Stock | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002304 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Carruthers WendyEVP, Human Resources
|
Exercise / conversionRestricted Stock Units · Derivative | 2,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002303 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,345 Underlying: Common Stock · 2,115 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Carruthers WendyEVP, Human Resources
|
Tax withholdingCommon Stock | 939 | $65.95 | $61,927.05 |
DisclosureSEC source: 0001225208-24-002303 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,854 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Carruthers WendyEVP, Human Resources
|
Exercise / conversionCommon Stock | 2,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002303 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionRestricted Stock Units · Derivative | 3,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002302 · doc4.xml · derivative · entry 4 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,518 Underlying: Common Stock · 3,172 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Tax withholdingCommon Stock | 1,408 | $65.95 | $92,857.60 |
DisclosureSEC source: 0001225208-24-002302 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,775 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionCommon Stock | 3,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002302 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002301 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,552 Underlying: Common Stock · 1,850 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Tax withholdingCommon Stock | 629 | $65.95 | $41,482.55 |
DisclosureSEC source: 0001225208-24-002301 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,799 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionCommon Stock | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002301 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002300 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,087 Underlying: Common Stock · 4,362 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 1,935 | $65.95 | $127,613.25 |
DisclosureSEC source: 0001225208-24-002300 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,569 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002300 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2024 Filed Mar 11, 2024 20:45 UTC Amendment |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Tax withholdingCommon Stock | 0 | $65.95 | $0.00 |
DisclosureSEC source: 0001225208-24-004027 · doc4a.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,575.99 F1 · kind: On February 14, 2024, upon the vesting of restricted stock units, the Issuer incorrectly withheld 1,378 shares of Boston Scientific common stock. This Form 4 is being amended to reflect that no shares were withheld for taxes. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 21:23 UTC |
LUDWIG EDWARD JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $17.37 | $0.00 |
DisclosureSEC source: 0001225208-24-002051 · doc4.xml · derivative · entry 3 LUDWIG EDWARD J · CIK 0001221783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,818 Underlying: Common Stock · 7,000 shares Expires 2025-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in full on May 3, 2016, the date of the Company's 2016 annual meeting of stockholders. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 21:23 UTC |
LUDWIG EDWARD JDirector
|
SaleCommon Stock | 7,000 | $65.03 | $455,223.30 |
DisclosureSEC source: 0001225208-24-002051 · doc4.xml · nonDerivative · entry 2 LUDWIG EDWARD J · CIK 0001221783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,374 Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 21:23 UTC |
LUDWIG EDWARD JDirector
|
Exercise / conversionCommon Stock | 7,000 | $17.37 | $121,590.00 |
DisclosureSEC source: 0001225208-24-002051 · doc4.xml · nonDerivative · entry 1 LUDWIG EDWARD J · CIK 0001221783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:23 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
GrantRestricted Stock Units · Derivative | 7,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002050 · doc4.xml · derivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,693 Underlying: Common Stock · 7,693 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:23 UTC |
Monson JonathanSVP, Global Controller and CAO
|
GrantStock Option (Right to Buy) · Derivative | 14,180 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002047 · doc4.xml · derivative · entry 2 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,180 Underlying: Common Stock · 14,180 shares Expires 2034-02-12 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:23 UTC |
Monson JonathanSVP, Global Controller and CAO
|
GrantRestricted Stock Units · Derivative | 4,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002047 · doc4.xml · derivative · entry 1 Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,616 Underlying: Common Stock · 4,616 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:22 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantStock Option (Right to Buy) · Derivative | 22,311 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002046 · doc4.xml · derivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,311 Underlying: Common Stock · 22,311 shares Expires 2034-02-12 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:22 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantRestricted Stock Units · Derivative | 8,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002046 · doc4.xml · derivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,462 Underlying: Common Stock · 8,462 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:22 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
GrantStock Option (Right to Buy) · Derivative | 20,282 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002049 · doc4.xml · derivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,282 Underlying: Common Stock · 20,282 shares Expires 2034-02-12 F1 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:22 UTC |
Sorenson John BradleyEVP, Global Operations
|
GrantStock Option (Right to Buy) · Derivative | 18,254 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002048 · doc4.xml · derivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,254 Underlying: Common Stock · 18,254 shares Expires 2034-02-12 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:22 UTC |
Sorenson John BradleyEVP, Global Operations
|
GrantRestricted Stock Units · Derivative | 6,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002048 · doc4.xml · derivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,924 Underlying: Common Stock · 6,924 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:22 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 144,516 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002045 · doc4.xml · derivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,516 Underlying: Common Stock · 144,516 shares Expires 2034-02-12 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:22 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantRestricted Stock Units · Derivative | 54,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002045 · doc4.xml · derivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,816 Underlying: Common Stock · 54,816 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
GrantStock Option (Right to Buy) · Derivative | 36,509 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002042 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,509 Underlying: Common Stock · 36,509 shares Expires 2034-02-12 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
GrantRestricted Stock Units · Derivative | 13,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002042 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,848 Underlying: Common Stock · 13,848 shares Expires 2028-02-12 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
GiftCommon Stock | 550 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002042 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Indirect · By Child Disclosed balance after: 4,894 F1 · balance_after: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002042 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,354 Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC |
Carruthers WendyEVP, Human Resources
|
GrantStock Option (Right to Buy) · Derivative | 18,254 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002041 · doc4.xml · derivative · entry 2 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,254 Underlying: Common Stock · 18,254 shares Expires 2034-02-12 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC |
Carruthers WendyEVP, Human Resources
|
GrantRestricted Stock Units · Derivative | 6,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002041 · doc4.xml · derivative · entry 1 Carruthers Wendy · CIK 0001563565 · EVP, Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,924 Underlying: Common Stock · 6,924 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:19 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
GrantStock Option (Right to Buy) · Derivative | 28,396 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002039 · doc4.xml · derivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,396 Underlying: Common Stock · 28,396 shares Expires 2034-02-12 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:19 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
GrantRestricted Stock Units · Derivative | 10,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002039 · doc4.xml · derivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,770 Underlying: Common Stock · 10,770 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:19 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
GrantStock Option (Right to Buy) · Derivative | 15,212 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002037 · doc4.xml · derivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,212 Underlying: Common Stock · 15,212 shares Expires 2034-02-12 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:19 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
GrantRestricted Stock Units · Derivative | 5,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002037 · doc4.xml · derivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,770 Underlying: Common Stock · 5,770 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:18 UTC |
Brennan Daniel J.EVP and CFO
|
GrantStock Option (Right to Buy) · Derivative | 38,537 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002036 · doc4.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,537 Underlying: Common Stock · 38,537 shares Expires 2034-02-12 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:18 UTC |
Brennan Daniel J.EVP and CFO
|
GrantRestricted Stock Units · Derivative | 14,617 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002036 · doc4.xml · derivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,617 Underlying: Common Stock · 14,617 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC |
Sorenson John BradleyEVP, Global Operations
|
Tax withholdingCommon Stock | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001782 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,336 Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC |
Sorenson John BradleyEVP, Global Operations
|
GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001782 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,808 F1 · kind: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2023 and subject to the completion of the concurrent three-year individual service period. On February 6, 2024, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 12,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001781 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,094 Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantCommon Stock | 26,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001781 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,254 F1 · kind: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2023 and subject to the completion of the concurrent three-year individual service period. On February 6, 2024, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 65,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001780 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,636,356 Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantCommon Stock | 146,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001780 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,403 F1 · kind: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2023 and subject to the completion of the concurrent three-year individual service period. On February 6, 2024, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Tax withholdingCommon Stock | 11,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001783 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,196.99 Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001783 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,775.99 F1 · kind: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2023 and subject to the completion of the concurrent three-year individual service period. On February 6, 2024, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Tax withholdingCommon Stock | 16,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001779 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,354 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.